$MAIA: An $80M Phase 3 oncology company with 17.8-month survival data, heavy insider buying, and partnerships with Regeneron, Roche and BeOne

{"summary": "Commenter challenges a bullish MAIA thesis, arguing the claimed Regeneron, Roche and BeOne partnerships do not exist and that the company is self-funded, which they see as a major red flag.", "reason": "The author provides a directional thesis to avoid MAIA based on the fundamental concern regarding the lack of claimed partnerships.", "ideas": [{"symbol": "MAIA", "direction": "avoid", "thesis": "The author argues the bullish MAIA thesis is flawed because the company does not actually have the major partnerships (Regeneron, Roche, BeOne) that the original post claims. They note the company is self-funded rather than funded through strategic partnerships, which they view as a significant red flag. The author also acknowledges most bio plays are binary events, which they say makes their concerns weigh even more heavily.", "thesis_short": "MAIA partnership claims false, self-funded red flag", "quote": "OP thinks they have these major partnerships when they do not. That’s a glaring red flag in their DD/Thesis.", "confidence": 0.65, "sentiment": -0.6, "timeframe": "unspecified"}], "model": "gemini-3.1-flash-lite", "verified": true, "extraction_model": "deepseek-v4-flash"}